A randomized controlled study of effectiveness between transcatheter arterial chemoembolization with fine powder cisplatin (IA-call) and transcatheter chemoembolization with Miriplatin for unresectable hepatocellular carcinomas(multicenter clinical trial PhaseII)
- Conditions
- nresectable hepatocellular carcinoma.
- Registration Number
- JPRN-UMIN000005425
- Lead Sponsor
- Japan community health care organization hitoyoshi medical center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1) Tumor thrombus in the main portal vein(VP4). 2) Remarkable arterio-portal shunt and arterio-venous shunt. 3) Uncontrollable ascites or pleural effusion. 4) Previous medical history of severe hypersensitivity. 5) Previous history of treatment using Cisplatin(IA-call) or Miriplatin(MILIPLA). 6) Serious complications as described below (Except chronic hepatitis and liver cirrhosis) i) Severe heart disease ii) Myocardial infarction within 6months iii) Renal failure iv) Active infection except viral hepatitis v) Active bleeding from the digestive tract vi) Another active cancers (besides hepatocellular carcinoma, the double cancers which can decide the prognosis). vii) Hepatic encephalopathy or severe psychiatric disease. 7) Pregnant women and women suspected of being pregnant. 8) Patients who are concluded to be inappropriate to participate in this study by the lead investigator and other physicians in charge.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method